Pain is common in cancer patients, particularly in the advanced stage of disease when the
prevalence is estimated to be more than 70%[1], contributing to poor physical and emotional …

Constipation is a common problem in patients with advanced cancer and a significant
source of major morbidity and distress, which is often under-appreciated [1]. Constipation is …

Purpose Opioid-induced constipation (OIC) is a frequent and debilitating adverse effect (AE)
of opioids—common analgesics for cancer pain. We investigated the efficacy and safety of a …

Background Opioid-induced constipation is a frequent side-effect of opioid treatment, and
standard interventions have limited or inconsistent efficacy. This study assessed the efficacy …

Purpose This randomized, double-blind, multicenter study aimed to determine the dose of
naldemedine, a peripherally-acting μ-opioid receptor antagonist, for future trials by …

Simple Summary Opioids are used in cancer pain management, however, their continuous
use may not be tolerable owing to adverse effects such as constipation, sleepiness, nausea …

Background Opioids provide effective relief from moderate‐to‐severe pain and should be
prescribed as part of a multifaceted approach to pain management when other treatments …

This paper is the thirty-eighth consecutive installment of the annual review of research
concerning the endogenous opioid system. It summarizes papers published during 2015 …

PURPOSE Opioid-induced constipation is the most frequent and non–self-limiting adverse
effect of opioid analgesia, reducing adherence and interfering with pain relief. This clinical …

Abstract Background Naldemedine (S‐297995) is a peripherally acting μ‐opioid receptor
antagonist developed as a once‐daily oral drug for opioid‐induced constipation (OIC) in …